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Abstract:  Ethanol affects cognition in a number of ways. Indirect effects include 
intoxication, withdrawal, brain trauma, central nervous system infection, hypoglycemia, 
hepatic failure, and Marchiafava-Bignami disease. Nutritional deficiency can cause pellagra 
and Wernicke-Korsakoff disorder. Additionally, ethanol is a direct neurotoxin and in 
sufficient dosage can cause lasting dementia. However, ethanol also has neuroprotectant 
properties and in low-to-moderate dosage reduces the risk of dementia, including Alzheimer 
type. In fetuses ethanol is teratogenic, and whether there exists a safe dose during pregnancy 
is uncertain and controversial. 
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1. Introduction 
 
The term “alcoholic” is applied to those who are psychically dependent (addicted) to ethanol—that 
is, craving for ethanol is a daily preoccupation. It is also applied to those who are physically dependent 
on ethanol—that is, cessation of drinking causes physical withdrawal symptoms and signs. The term is 
sometimes extended to include “problem drinkers”, who may be neither psychically nor physically 
dependent on ethanol but who get into trouble when they drink [1]. In the United States it is estimated 
that 7% of adults and 19% of adolescents are alcoholics or problem drinkers and that ethanol accounts 
for more than 100,000 deaths per year or 5% of all mortality [2]. As with other reinforcing drugs, 
alcohol addiction—i.e., compulsive use, craving—depends on mesolimbic dopaminergic pathways of 
the so-called “reward system” [3]. 
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2. Indirect Effects 
 
Ethanol can alter mentation in a variety of ways. Affecting many neurotransmitter systems, ethanol 
inhibits excitatory glutamate receptors and facilitates inhibitory  γ-aminobutyric  acid  (GABA)  
receptors [4]. Early symptoms of acute intoxication—euphoria and disinhibition—progress to stupor 
and respiratory depression  [5].  Perhaps reflecting glutamate receptor up-regulation and   
GABA-receptor down-regulation, abrupt abstinence after prolonged or binge drinking can result in 
tremor, hallucinations (visual, auditory, or tactile), seizures, or delirium tremens, with severely 
constricted attentiveness, fluctuating levels of alertness, agitation, and autonomic instability [6-8]. It is 
possible, moreover, that repeated binges and withdrawals cause not only early abstinence symptoms 
but also glutamate-induced excitotoxicity and permanent neuronal damage, in turn contributing to 
more lasting neurological disorders, including dementia.  
Other causes of acutely altered mentation in heavy drinkers  include cerebral trauma  [9],  
meningitis  [10], hypoglycemia  [11],  hepatic encephalopathy  [12], alcoholic ketoacidosis  [13]  and 
concomitant use of other agents such as cocaine or heroin [1]. Marchiafava-Bignami disease, a rare 
disorder nearly always diagnosed in alcoholics, causes mania, depression, paranoia, and dementia, plus 
seizures, paresis, and ataxia, and often progresses to coma and death within a few months; symptoms 
are not readily explained by the prominent corpus callosum demyelination that is the pathological 
hallmark of this poorly understood disease [14]. 
 
3. Nutritional Deficiency Disorders 
 
Often deficient in thiamine, nicotinic acid, other B vitamins, and folate, alcoholics frequently 
develop neurological disorders associated with malnutrition, including cerebellar degeneration, 
amblyopia, polyneuropathy, and disorders affecting cognition. In pellagra nicotinic acid deficiency 
results in skin, gastrointestinal, and mental abnormalities which can progress to memory impairment, 
delusions, hallucinations, dementia, or delirium; hypertonus and startle myoclonus may be present. 
Symptoms usually improve following treatment with nicotinic acid or nicotinamide [15]. 
A  more frequently encountered nutritional disorder in alcoholics is Wernicke–Korsakoff  
disease  [16].  Wernicke and Korsakoff syndromes share the same pathology—characteristic 
histological abnormalities within the medial and anterior thalamus, hypothalamus (including  the 
mammillary bodies), and periaqueductal grey matter of the midbrain, but they have different clinical 
features.  Wernicke syndrome consists of abnormal mentation, abnormal eye movements, and gait 
ataxia.  Mental abnormalities include varying combinations  of inattentiveness, abulia (apathy), and 
impaired memory progressing in the absence of treatment to coma. Eye movement abnormalities begin 
with limitations of abduction or horizontal gaze and progress to ophthalmoplegia.  Gait ataxia 
progresses to inability to stand. Patients are thiamine-deficient, and symptoms rapidly improve when 
thiamine is replaced in a timely fashion. Improvement is often less than complete, however. A patient 
may be left with nystagmus and a broad-based gait, and the multi-domain cognitive impairment may 
evolve into a more selective amnestic disorder—Korsakoff syndrome. How often Korsakoff syndrome 
occurs in the absence of antecedent Wernicke syndrome is uncertain.  Autopsies have revealed Int. J. Environ. Res. Public Health 2010, 7                 
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Wernicke-Korsakoff pathology in patients unsuspected of having Wernicke syndrome prior to   
death [17]. 
Clinical evidence suggests that Wernicke syndrome is more likely to occur in nutritionally deficient 
alcoholics than in comparably deficient non-alcoholics. In developing countries, thiamine deficiency in 
a non-alcoholic  is more likely to produce beri-beri with cardiac failure and polyneuropathy than 
Wernicke syndrome [18]. (On the other hand, several of Korsakoff’s original patients had not been 
heavy drinkers [19].) A biologically plausible mechanism by which thiamine deficiency and ethanol 
could have additive or even synergistic effects on cognition involves glutamate. Thiamine deficiency 
causes excessive glutamate release and thus like ethanol has the potential to cause excitotoxic neuronal 
damage [20]. When thiamine-induced glutamate release is combined with ethanol-induced glutamate 
receptor up-regulation, the potential for excitotoxicity would be compounded. In anecdotal reports 
patients with Wernicke-Korsakoff syndrome have experienced symptomatic improvement following 
treatment with the glutamate NMDA receptor antagonist memantine  [21,22].  (They have also 
reportedly improved after treatment with cholinergic agents such as donepezil and   
rivastigmine [23,24].) 
A combined effect of nutritional deficiency and direct ethanol toxicity appears operative in other 
neurological disorders encountered in alcoholics.  Cerebellar degeneration can occur with severe 
nutritional deprivation in both drinkers and non-drinkers  [25,26].  Animal studies, however, 
demonstrate neurotoxic effects of ethanol on cerebellar granule and Purkinje cells [27,28].  Optic 
atrophy in heavy drinkers (formerly called “tobacco-alcohol amblyopia”) improves with nutritional 
supplementation, but it is likely that ethanol toxicity (as well as, perhaps, neurotoxic compounds in 
tobacco smoke) are contributory [29]. Polyneuropathy in alcoholics similarly appears to have two 
causes.  In a study comparing polyneuropathy in thiamine-deficient drinkers, thiamine-deficient  
non-drinkers, and  alcoholics without thiamine deficiency, polyneuropathy attributable to thiamine 
deficiency alone was motor-dominant and rapidly progressive, impaired both superficial and deep 
sensation, and caused predominantly large-fiber axonal loss. Polyneuropathy in alcoholics without 
thiamine deficiency was sensory-dominant, slowly progressive, impaired superficial sensation, and 
caused predominantly small-fiber axonal loss. Thiamine-deficient alcoholics tended to have a mixture 
of the two types [30]. 
 
4. Alcoholic Dementia 
 
In recent decades it has become increasingly evident that ethanol can cause  lasting cognitive 
impairment—“alcoholic dementia” or “ethanol-related dementia”—in the absence  of nutritional 
deficiency, cerebral trauma, hepatic failure, or other indirect forms of brain injury. Many alcoholics 
demonstrate gradually progressive multi-domain cognitive impairment rather than a more restrictive 
amnestic disorder, a prior history of Wernicke syndrome is often lacking, and there may be little 
evidence of past or present nutritional deficiency. Computerized tomographic (CT) scanning shows 
ventricular and sulcal enlargement unexplained by the neuropathology of Wernicke-Korsakoff 
syndrome, and the observed brain shrinkage reportedly improves with abstinence [31-33]. 
Ethanol-related dementia has been estimated to represent roughly 10% of all cases of dementia, and 
“heavy alcohol use” probably contributes to many more [32,33]. Proposed criteria for ethanol-related Int. J. Environ. Res. Public Health 2010, 7                 
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dementia include dementia for at least 60 days after last exposure to ethanol, minimum 35 standard 
drinks per week for males and 28 for females for more than 5 years, and significant ethanol use within 
3 years of the onset of impaired cognition [34,35]. 
Animal studies using pair-fed controls confirm that ethanol is neurotoxic, and in exposed animals 
neuropathological changes correlate with impaired memory and learning  [36,37].  Reported 
abnormalities include loss of hippocampal CA1 and CA3 pyramidal neurons, mossy fiber-CA3 
synapses, and dentate granule cells; loss of cholinergic neurons in the basal forebrain; pathological 
changes in neurons of cerebral cortex, hypothalamus, and brainstem; and impaired pruning of 
redundant cortical synapses during early development [38-44]. Damage is dose-related and especially 
likely with binge drinking that produces high blood ethanol concentrations (BEC) [45]. 
Nutritional deficiency can be difficult to exclude in cognitively impaired heavy drinkers, but there 
is convincing evidence of brain damage in “uncomplicated alcoholics” [46]. Transcranial magnetic 
stimulation in chronic alcoholics demonstrates significant prolongation of central motor conduction 
time  [47].  Quantitative neuroimaging suggests  association of cognitive impairment with damaged 
pontocerebellar and cerebellothalamocortical systems  [48].  Cerebral white matter volume loss is 
prominent, and MRI, including diffusion-weighted imaging, reveals involvement of structural 
elements rather than water loss [49,50]. Such changes in cerebral white matter are at least partly 
reversible, although it is less clear whether cognitive improvement accompanies improvement on 
imaging [51,52]. Magnetic resonance spectroscopy reveals damage to white matter phospholipids in 
the absence of white matter volume loss  [53].  White matter abnormalities, including excessive   
intra- and extracellular fluid, have also been identified with diffusion tensor imaging [54]. 
In human studies neuronal loss is described in many brain areas, most consistently the superior 
frontal association cortex, hypothalamus, and cerebellum, and less consistently the hippocampus, 
amygdala, and locus coeruleus  [46].  Basal ganglia and serotonergic raphe nuclei appear to be 
unaffected [32,55]. Using the neuronal/axonal marker N-acetyl aspartate (NAA), magnetic resonance 
spectroscopy confirmed the special vulnerability of pre-frontal cortex in alcoholics, and abnormalities 
in planning, organization, problem solving, and abstracting, as well as lack of insight, disinhibition, 
and perseveration are consistent with these regional vulnerabilities [55-58]. Early changes in dendrites, 
receptors, and neurotransmitters probably produce cognitive impairment in advance of gross 
morphological change [59]. Women appear to be more susceptible than men to the adverse effects of 
ethanol, exhibiting earlier changes yet greater recovery with abstinence  [60].  The likelihood of 
cognitive impairment may be greater in subjects with repeated prior episodes of symptomatic 
withdrawal [61]. 
Ethanol neurotoxicity may have several mechanisms, including glutamate  excitotoxicity and 
oxidative stress, exacerbated in some cases by thiamine deficiency [55,62-64]. In an open label study 
of 19 patients with probable ethanol-related dementia, cognitive improvement followed treatment with 
the glutamate NMDA receptor antagonist memantine [21]. (As noted, Wernicke-Korsakoff syndrome 
also reportedly benefits from memantine therapy [22].) In rat hippocampal slice cultures subjected to 
10 days of in vitro ethanol followed by 24 hours of withdrawal, memantine effectively blocked ethanol 
withdrawal-induced neurotoxicity [65]. (Interestingly, memantine also appears to reduce craving in 
subjects dependent on ethanol [66].)  Int. J. Environ. Res. Public Health 2010, 7                 
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Homocysteine is also implicated in ethanol neurotoxicity; hyperhomocysteinemia follows folate 
deficiency, and homocysteine acts as an agonist at glutamate NMDA receptors, increasing NMDA 
receptor transmission and the potential for excitotoxicity [67-69]. Ethanol also reduces the availability 
of brain-neurotrophic factor and nerve growth factor, possibly resulting in impaired intracellular 
signaling pathways [70]. Ethanol-induced DNA strand breaks might cause neuronal death [71]. In 
animals protein adduct formation with the ethanol metabolite acetaldehyde was found in frontal lobe 
cortex and white matter [72]. 
Just  as thiamine deficiency may interact synergistically with alcohol neurotoxicity to produce 
cognitive impairment, other neurological disorders encountered in alcoholics, including hepatic 
encephalopathy and prior cerebral trauma or hypoglycemia, could also be contributory. Also operative 
might be age of onset of drinking and genetic vulnerability [73,74]. 
Attempts to define a safe dose threshold for ethanol have been inconsistent.  A review of 19 
published studies addressing this issue concluded that 5 or 6 “standard drinks” per day over extended 
periods resulted in “cognitive inefficiencies”, that 7 to 9 drinks per day resulted in “mild cognitive 
deficits”, and that 10 or more drinks per day caused impaired cognition of a degree encountered in 
frank alcoholics [75]. In some studies heavy ethanol consumption (average 418g ethanol per week) 
correlated with reduced frontal lobe volume, whereas moderate consumption (181g per week) and light 
consumption (average 88g per week) did not  [76].  Some studies, moreover, found that   
light-to-moderate ethanol intake reduced the likelihood of dementia [77-86]. 
 
5. Ethanol as a Neuroprotectant 
 
5.1. Reducing the Risk of Coronary Artery Disease and Ischemic Stroke 
 
Relevant to such a protective effect of mild-to-moderate drinking on cognitive decline are its 
complex effects on coronary artery disease (CAD) and ischemic stroke. Numerous epidemiological 
studies, including prospective cohort studies, provide powerful evidence that one half to 2 drinks per 
day reduce the risk of myocardial infarction by roughly 25%, with 6 or more drinks per day increasing 
the risk [87-89]. The result is a J-shaped curve, with mild-to-moderate ethanol intake reducing risk of 
CAD compared to non-drinking but heavy ethanol intake increasing risk. Concern has been expressed 
that the apparent protective effect is overestimated when non-drinkers are combined with former 
drinkers, who might have stopped  drinking for reasons of ill health  [90,91].  However, separating 
former drinkers from longer-term abstainers in a large cohort study did not alter the results [92,93]. 
Similarly, the protective effects remained after correcting for sociodemographic and other clinical 
characteristics [93]. Benefit has been found for red and white wine, beer, and liquor [93]. 
A number of mechanisms appear to explain ethanol’s protective effect. Ethanol raises blood levels 
of high density lipoprotein cholesterol (HDL-C) in a dose-dependent fashion, and some studies suggest 
that this effect accounts for at least half of the protection against CAD [94]. Ethanol also lowers high-
density lipoprotein cholesterol, increases insulin sensitivity [95], prevents platelet aggregation [96], 
increases fibrinolysis [97], opposes thrombin activity [87], and reduces inflammatory markers [98]. In 
addition, animal studies demonstrate a direct protective effect of ethanol on cardiac myocytes rendered Int. J. Environ. Res. Public Health 2010, 7                 
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ischemic; this effect has been linked to ethanol’s interactions with protein kinase C, adenosine 
receptors, and “cardioprotective proteins” that include superoxide dismutase, nitric oxide synthase, and 
heat shock proteins [87]. It is speculated that some of the benefit might be attributable to antioxidant 
polyphenols such as resveratrol, which are especially abundant in red wine [99-101]. In a rat model of 
cerebral infarction resveratrol reduced infarct volume, and the neuroprotection correlated with 
downregulation of inducible nitric oxide synthase (iNOS) and upregulation of endothelial nitric oxide 
synthase (eNOS) [102]. 
A similar J-shaped curve describes the association of ethanol intake and ischemic stroke, although 
the protective effects of low-to-moderate intake are less dramatic. Meta-analysis of 19 cohort studies 
and 16 case-control studies (selected from a total of 122 reports) found that compared with abstention, 
consumption of less than 12 g ethanol per day reduced the risk of total stroke (relative risk, RR: 0.80); 
consumption of 12 to 24 g per day reduced the risk of ischemic stroke (RR: 0.72); and consumption of 
more than 60 g per day increased the risk of total stroke (RR: 1.64), ischemic stroke (RR:1.69), and 
hemorrhagic stroke (RR: 2.18).  Light-to-moderate  ethanol intake did not reduce the risk of 
hemorrhagic stroke [103]. Subsequent cohort studies have shown comparable results [104,105]. It is 
likely that similar effects on serum lipoproteins, coagulation factors, and platelets contribute to the 
reduced risk of both myocardial infarction and ischemic stroke conferred by low doses of ethanol, and 
antioxidants such as resveratrol (as well as the antioxidant properties of ethanol itself) might provide 
neuroprotection to the brain [87]. In animal models of ischemic stroke, prior ethanol reduced delayed 
neuronal death, neuronal and dendritic degeneration, oxidative DNA damage, glial cell activation, and 
neutrophil infiltration [106]. 
 
5.2. Reducing the Risk of Dementia 
 
The possibility that ethanol confers direct neuroprotection to the brain has obvious bearing on the 
apparent risk reduction of dementia in selected drinkers. Once again a J-shaped curve emerges, with 
moderate intake reducing the risk of cognitive impairment and heavy drinking increasing it [77,78]. In 
the French PAQUID Study dementia was less prevalent among wine-drinkers, implicating anti-oxidant 
polyphenols, but few subjects in that study drank beer or liquor [79,107,108]. Studies from around the 
world include the French PAQUID Study [79,107,108], the French Epidemiology of Vascular Aging 
Study [109], the National Heart Lung and Blood Institute Twin Study [110], the Rotterdam Study [80], 
the Copenhagan City Heart Study  [81],  the  Chinese  Nanjing University Study [111],  the Italian 
Longitudinal Study on Aging [112,113], the Cardiovascular Health Study [82], the Nurses’ Health 
Study [114], the Washington Heights Inwood Columbia Aging Project [115], and the Prospective 
Population Study of Women in Göteborg, Sweden [116]. 
Studies have been both cohort [80,109-116] and case-control  [81,82], and subjects’ ages at 
enrollment have varied—in one study 59 to 69 years [110], in another 70 to 81 years [114]. Study 
design has included enrollment of subjects considered cognitively normal or “non-demented” at   
outset [80,81], enrollment of subjects with “mild cognitive impairment” [111,112], and case-control 
analysis of demented subjects [82]. In some studies protection from cognitive decline was conferred 
only by wine [79,81,107,108,115,116]; others found either wine, beer, or liquor to be   
protective [80,82,112,114]. In some studies, benefit was evident only in subjects carrying an APOEε4 Int. J. Environ. Res. Public Health 2010, 7                 
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allele, or an APOEε4  allele enhanced  the  protective  effect [80,110]. In other studies, benefit was 
evident  only  in  subjects  lacking  an  APOEε4  allele,  or  an  APOEε4  allele  reduced  the  protective  
effect [82,109,112,115]. One study found no effect of APOEε4 genotype on risk reduction [114]. 
A 2008 meta-analysis reviewed 23 studies addressing the association of ethanol and incident 
dementia or cognitive decline  [117].  Twenty studies were epidemiological cohort and 3 were   
case-control nested in a cohort. The authors concluded that small amounts of ethanol probably protect 
against dementia (RR: 0.63) and Alzheimer disease (RR: 0.57) but not against vascular dementia  
(RR: 0.82, non-significant) or cognitive decline (RR: 0.89, non-significant). Studies varied as to what 
constituted optimal consumption or what defined a “standard drink.” Overall the evidence supported 
special benefit conferred by wine (but little evidence to favor red wine over white wine) and greater 
benefit in subjects lacking an APOEε4 allele. Two studies addressing concern that combining former 
drinkers with non-drinkers might result in spurious protection found that the positive benefit for 
ethanol was maintained when former drinkers were excluded [82]. The authors of the meta-analysis 
emphasized that association is not the same as causation and that moderate drinkers, compared to 
abstainers and heavy drinkers, might “live healthier lives”. 
Mild-to-moderate consumption of ethanol nonetheless  appears to reduce the risk of dementia 
among older people, and the favorable effects of ethanol on cerebrovascular disease do not explain the 
benefit in non-vascular dementia.  Animal models are consistent with these observations.  
“Alcohol-preferring” rats chronically consuming 15% ethanol/water were protected from apoptosis 
caused by inflammatory lipopolysaccharide injection [119]. In brain cultures non-neurotoxic ethanol 
exposure protects against excitotoxic NMDA receptor mediated neurodegeneration, and the benefit 
paralleled induction of heat shock proteins  [120,121].  Neuroprotective effects, including those of 
polyphenol antioxidants as well as the antioxidant effects of ethanol itself, are plausible mechanisms 
for these effects. The Rotterdam Study investigators speculated that the greater benefit of ethanol 
among subjects with an APOEε4 allele might be related to ethanol’s ability to block oxidation of the 
apolipoprotein, thereby preventing it from binding to β-amyloid [80]. Most studies, however, showed 
greatest benefit among subjects lacking an APOEε4 allele [117]. 
Perhaps surprisingly, the apparent neuroprotection observed in most epidemiological studies has not 
been reflected in imaging studies. Framingham Study investigators tested the hypothesis that moderate 
ethanol consumption would be associated with less age-related brain volume reduction and white 
matter lesions compared to either no drinking or heavy drinking [122]. Not only was moderate ethanol 
intake not protective, but reduction in brain volume had a negative linear association with the amount 
of ethanol consumed (“abstainers”, “former drinkers”, “low”, “moderate”, “high”). Other studies also 
reported increased ventricular size [123,124], reduced grey matter volumes [125], or “brain   
atrophy” [126] with increasing amounts of ethanol consumption. Two studies did demonstrate fewer 
cerebral white matter lesions in moderate drinkers [123,127]. 
 
6. Ethanol’s Effects on the Fetus 
 
The fetal effects of ethanol involve a different kind of neurotoxicity. The fetal alcohol syndrome 
(FAS) is a triad consisting of CNS dysfunction, intrauterine growth deficiency, and distinctive facial 
dysmorphism; less often there are anomalies of the heart, skeleton, urogenital organs, skin and   Int. J. Environ. Res. Public Health 2010, 7                 
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muscles [128,129]. Symptoms include mental retardation, hypotonia, poor coordination, hyperactivity, 
and behavioral problems.  Neuropathological features include microcephaly, abnormal cortical 
thickness, reduced cerebral white matter volume, and abnormalities of the corpus callosum and 
cerebellar vermis. Long-term follow-up demonstrates that mental retardation, abnormal behavior, and 
facial dysmorphism persist  into adulthood [130].  It is also evident that cognitive and behavioral 
abnormalities can occur in the absence of dysmorphisms, so-called “fetal alcohol effects”, “alcohol-
related neurodevelopmental disorder”, (ARND) or “fetal alcohol spectrum disorders” [131-136]. 
Carefully controlled animal studies confirm that ethanol toxicity is the cause of FAS and that lower 
doses can produce impaired mental ability without other physical signs [137]. Interestingly, although 
in humans with FAS the hippocampi are reportedly normal-sized, in rodents exposed in utero to 
ethanol the hippocampi display reduced number of neurons and dendritic spine density, correlating 
with the animals’ impaired learning and memory [138]. Ethanol disrupts numerous developmental 
events in animal models, including neurogenesis, cell migration, cell adhesion, neuron survival, axon 
outgrowth, synapse formation, and neurotransmitter function [139-141].  Animal studies include 
reports that “low-to-moderate” amounts of ethanol, a binge pattern of consumption, or even single 
exposures, can cause features of FAS [142-144].  
Epidemiological studies in humans similarly raise the question of whether a “safe dose” of 
intrauterine ethanol exposure exists, with reports of FAS, low birth weight,  decreased head 
circumference,  dysmorphism, or subtle neurological and behavioral effects associated with 100  g 
ethanol per week, 10 g per day, or even 0.1 oz. per day [145-148]. The validity of animal and human 
studies claiming teratogenicity of such low doses has not gone unchallenged, however, and whether 
there is a threshold of safety remains controversial [149-150]. So are estimates of FAS prevalence, 
which range from 0.5 to 2.0 per 1000 births in the United States [151] to 0.06 per 1000 births in 
Australia [152] to 3.7–7.4 per 1000 in the Lazio province of Italy [153]. 
Proposed mechanisms for ethanol teratogenicity (not mutually exclusive) include vasospasm and 
CNS ischemia [154]; blockade at glutamate NMDA receptors (which in fetal brain play a crucial role 
in neuronal differentiation) [155]; inhibition of the action of a neuronal cell adhesion molecule, L1, 
which in fetal brain mediates neurite outgrowth [156]; and excessive activation of glycogen synthase 
kinase 3β, a serine/threonine kinase that regulates fetal neurogenesis, neuronal migration, synapse 
formation, and neuronal survival [141]. 
 
7. Conclusions 
 
Identifying the mechanisms of ethanol’s multiple effects on cognition—including neurotoxicity, 
neuroprotection, interaction with nutritional deficiency, and teratology—will have obvious bearing not 
only on medical management but also on public policy. 
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